Friday, July 6, 2018

Dynacure launches with $55 million and Ionis antisense oligonucleotide drug

The French startup will develop an RNA-targeted therapy for the rare muscle disease centronuclear myopathy

via Chemical & Engineering News: Biological SCENE https://ift.tt/2KCk9wp
Posted by at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)